Gala vs SnagRx

Neither Gala nor SnagRx has an FDA warning letter on record. On compounded semaglutide injection, SnagRx costs $960 less a year at standing rates: $99 a month against $179 a month at Gala. It is one of two products the two sell at comparable terms.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Gala / SnagRx

Gala logo

Gala

8.5/10

SnagRx logo

SnagRx

9.2/10

FDA warning letters
None on record
None on record
Pharmacy
None named in our record
Lowest standing price
$179/moCompounded semaglutide injection
$99/moCompounded semaglutide injection
States
All 50 states
49 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026

Both Gala and SnagRx are affiliate partners: we are paid if you sign up through our links. Neither is featured. Scores are computed the same way for both (Gala 8.5, SnagRx 9.2). How we are paid

What the record shows

  1. 01

    Neither Gala nor SnagRx has an FDA warning letter on record.

  2. 02

    SnagRx names four pharmacies. Gala names no compounding pharmacy in our record.

  3. 03

    On compounded semaglutide injection, SnagRx costs $960 less a year at standing rates: $99 a month against $179 a month at Gala. It is one of two products the two sell at comparable terms.

  4. 04

    Only Gala lists a price for brand-name semaglutide pen.

  5. 05

    Gala covers one state SnagRx does not.

  6. 06

    Gala states you can cancel at any time; SnagRx does not state its cancellation terms.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Gala

SnagRx

Compounded semaglutide injection

$179/mo

$2,148 a year

$99/moLower

$1,188 a year

Compounded tirzepatide injection

$179/mo

$2,148 a year

$149/moLower

$1,788 a year

Brand-name semaglutide pen

$1,299/mo

$15,588 a year

Not sold or not priced
Price includes
Medication, clinician visits, shipping
Medication, clinician visits, shipping
Cancel any time
Yes, stated
Not stated
Minimum term
Yearly plan for the $179 rate; 72 hours' notice before the billing date to cancel
Not stated
Refunds
No refund on cancellation; full refund only if the medical provider disqualifies you
Not stated

Read off each seller’s own pages. Gala: October 17, 2026. SnagRx: October 17, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Gala

8.5/10
  • Sells brand-name semaglutide pen, which SnagRx does not price
  • States you can cancel at any time
  • Names no compounding pharmacy

The case for SnagRx

9.2/10
  • $960 a year less on compounded semaglutide injection
  • $360 a year less on compounded tirzepatide injection
  • Names its compounding pharmacy

Scores

Gala 8.5 · SnagRx 9.2 out of 10. Six weighted parts.

Value25%

7.9A
vs
B
10.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

7.5A
vs
B
9.0

Accessibility10%

10.0A
vs
B
9.8

Support10%

7.0A
vs
B
7.0

The score is the same formula for every seller. Payment does not enter it. Method

Gala vs SnagRx: questions

Neither Gala nor SnagRx has an FDA warning letter on record. Letters are matched to a seller by company, domain and address, never by a similar name.
SnagRx names four pharmacies. Gala names no compounding pharmacy in our record. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
SnagRx, by $960 a year at standing rates. Gala: $179 a month, about $2,148 a year. SnagRx: $99 a month, about $1,188 a year.
Gala states you can cancel at any time; refunds: no refund on cancellation; full refund only if the medical provider disqualifies you. SnagRx does not state its cancellation terms.
Both Gala and SnagRx are affiliate partners: we are paid if you sign up through our links. Neither is featured. Scores are computed the same way for both (Gala 8.5, SnagRx 9.2).

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks